Molecular Targeting Technologies, Inc.
MTTI is a clinical stage company transforming the lives of patients with severe and life-threatening diseases thru innovative targeted theranostics.
EBTATE (177Lu-EB-DOTA-TATE) radiotherapeutic targets somatostatin receptors in neuroendocrine neoplasms. EBTATE shows several-fold increase of blood half-life and enhanced tumor uptake over existing PRRTs. Treatments using either 1.85 or 3.7 GBq EBTATE in NET patients were well tolerated and more effective than 3.7 GBq of 177Lu-DOTA-TATE (Lutathera®). Acquired under an exclusive global license from NIH. Enters clinical trials in the US in Q4 2020.
EBRGD (177Lu-EB-DOTA-RGD) is a selective, cancer fighting radiotherapeutic targeting αvβ3-expressing tumors. Studies are currently focused on non-small cell lung cancer and glioblastoma multiforme. Will enter clinical trials in 2021. Acquired under an exclusive global license from NIH.
TDURA (99mTc-duramycin) radiodiagnostic targets PE, externalized in dying cells. Clinical trials imaging colorectal tumor response to chemotherapy begin in Q3 2020.
FGA (18F-fluoroglucaric acid) radiodiagnostic targets histones to detect necrosis and apoptosis, tracking tumor response to therapy. MTTI owns a proprietary, low cost route from FDG. FGA holds promise in a range of diseases.
Our Team: Seasoned executives from multinational pharmaceutical companies, each with a successful track record.
Brands: EBTATE (177Lu-EB-DOTA-TATE)
FGA (18F-fluoroglucaric acid)